Article title: Trastuzumab biosimilars vs trastuzumab originator in the treatment of HER2-positive breast cancer: a systematic review and network meta-analysis
Authors: Liu, T., Liu, D., Jin, Y., and Dong, M.
Journal: Immunopharmacology and Immunotoxicology
DOI: 10.1080/08923973.2022.2090956
When the above article was first published online, the note was missing from Figure 3 caption.
The Figure 3 caption should read as follows:
Figure 3. Forest plot of the network meta-analysis. (A) Overall Response Rate; (B) Pathological Complete Response; (C) Serious Adverse Events.
Note: A ratio of greater than 1 means that Herceptin has a higher probability of positive events. A ratio of less than 1 means that the probability of positive events of Trastuzumab biosimilars is high.